Chronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight

The chronic pain market is expected to witness steady growth, driven by the rising prevalence of chronic diseases, musculoskeletal disorders, neuropathic pain, arthritis, and age-related conditions. Additionally, the expected launch of emerging therapies such as SL1002 (Saol Therapeutics), Zenagamtide (Novo Nordisk), AbobotulinumtoxinA (DYSPORT; Ipsen), AncobotulinumtoxinA (XEOMIN; Merz Therapeutics), Retatrutide (LY3437943; Eli Lilly and Company), Suzetrigine (JOURNAVX; Vertex Pharmaceuticals), Esreboxetine (AXS-14; Axsome Therapeutics), and others will further accelerate the market growth. LAS VEGAS, Sept.